Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing

Core Points - Helix BioPharma Corp. has extended its Annual General and Special Meeting to March 26, 2025, to seek shareholder approval for proposed asset acquisitions and financing [1][2] - The company has applied to the Ontario Superior Court for permission to hold the meeting by the new date, with a hearing scheduled for February 26, 2025 [2] - The Toronto Stock Exchange has acknowledged the extension, and the company plans to hold another annual general meeting before January 31, 2026 [3] Asset Acquisitions - The proposed asset acquisitions are from Laevoroc Immunology AG and Laevoroc Chemotherapy AG [1] - Additional information regarding these acquisitions can be found in the company's news releases dated November 29, December 2, and December 6, 2024 [4] Shareholder Participation - Shareholders of record as of January 31, 2025, are entitled to vote at the meeting, and they are encouraged to vote in advance using the provided instructions [5] - Proxies must be received by 10 a.m. (EST) on March 24, 2025 [5] Company Overview - Helix BioPharma Corp. is focused on developing novel therapies for hard-to-treat cancers, with a pipeline that includes a clinical-stage proprietary technology platform of bioconjugates targeting CEACAM6-expressing solid tumors [7] - The lead candidate, Tumour Defence BreakerTM L-DOS47, is an antibody-enzyme conjugate that aims to enhance anti-cancer immunity and has completed Phase Ib studies in non-small cell lung cancer [7]